|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:approvalYear
|
1993
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05AX08
|
|
gptkbp:blackBoxWarning
|
increased mortality in elderly patients with dementia-related psychosis
|
|
gptkbp:chemicalFormula
|
C23H27FN4O2
|
|
gptkbp:contraindication
|
hypersensitivity to risperidone
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
3-20 hours
|
|
gptkbp:form
|
gptkb:tablet
oral solution
long-acting injection
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:risperidone
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Risperdal
|
|
gptkbp:interactsWith
|
gptkb:paroxetine
gptkb:levodopa
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:fluoxetine
CYP2D6 inhibitors
other CNS depressants
antihypertensive drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
1994 (US)
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2003
|
|
gptkbp:pregnancyCategory
|
C (US)
B (Australia)
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
seizures
QT prolongation
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
weight gain
drowsiness
extrapyramidal symptoms
gynecomastia
increased prolactin
diabetes risk
|
|
gptkbp:usedFor
|
bipolar disorder
schizophrenia
irritability associated with autism
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|